| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
10,120 |
8,184 |
$4.98M |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
4,478 |
4,367 |
$1.59M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
9,613 |
7,914 |
$1.48M |
| 36415 |
Collection of venous blood by venipuncture |
11,133 |
10,317 |
$1.07M |
| 80305 |
|
9,242 |
7,472 |
$878K |
| 84443 |
Thyroid stimulating hormone (TSH) |
5,465 |
5,298 |
$833K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
6,218 |
6,027 |
$503K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,793 |
2,698 |
$471K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
944 |
810 |
$324K |
| 81003 |
|
1,725 |
1,628 |
$322K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
589 |
519 |
$299K |
| 80074 |
|
982 |
953 |
$281K |
| 80061 |
Lipid panel |
5,248 |
5,085 |
$251K |
| 86703 |
|
963 |
938 |
$245K |
| 85027 |
|
4,108 |
3,975 |
$228K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
273 |
266 |
$176K |
| 36416 |
|
770 |
740 |
$166K |
| 84436 |
|
2,056 |
1,993 |
$128K |
| 80053 |
Comprehensive metabolic panel |
7,660 |
7,364 |
$120K |
| 99000 |
|
608 |
595 |
$93K |
| 83735 |
|
767 |
746 |
$74K |
| 82043 |
|
403 |
390 |
$56K |
| 82728 |
|
2,224 |
2,164 |
$56K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
232 |
223 |
$56K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
79 |
79 |
$53K |
| 82607 |
|
2,356 |
2,301 |
$49K |
| 82746 |
|
2,325 |
2,271 |
$45K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
142 |
139 |
$44K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
60 |
60 |
$41K |
| 81025 |
|
193 |
187 |
$40K |
| 82248 |
|
64 |
62 |
$31K |
| 83014 |
|
57 |
56 |
$26K |
| 86376 |
|
816 |
800 |
$18K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
54 |
52 |
$16K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
79 |
79 |
$13K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
66 |
22 |
$12K |
| 83655 |
|
13 |
13 |
$7K |
| 84439 |
|
2,525 |
2,451 |
$6K |
| 86800 |
|
818 |
801 |
$5K |
| 82570 |
|
399 |
384 |
$5K |
| 83550 |
|
2,226 |
2,166 |
$4K |
| 84153 |
|
40 |
40 |
$2K |
| 81015 |
|
221 |
211 |
$2K |
| 0240U |
|
23 |
23 |
$2K |
| 85018 |
|
82 |
80 |
$2K |
| 84480 |
|
819 |
803 |
$1K |
| 85652 |
|
39 |
39 |
$1K |
| 83540 |
|
2,226 |
2,165 |
$1K |
| 82962 |
|
13 |
13 |
$958.00 |
| 84100 |
|
14 |
14 |
$0.00 |